Serum tumor markers expression (CA199, CA242, and CEA) and its clinical implications in type 2 diabetes mellitus

doi:10.4239/wjd.v15.i2.232

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1692)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

965

Figures (1-1)

120

Tables (1-5)

113

Sum=1263

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

242

Sum=332

Feb 15, 2024 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Diabetes. Feb 15, 2024; 15(2): 232-239
Published online Feb 15, 2024. doi: 10.4239/wjd.v15.i2.232

Table 1 General characteristics was compared between two groups

Variables	Control group (n = 51)	T2DM group (n = 82)	χ²/Z/t value	P value
Gender (male/female)	27/24	47/35	0.244	0.621
Age (yr)	57.98 ± 11.72	59.02 ± 11.58	0.503	0.616
ALT (U/L)	18.40 (13.20, 28.30)	18.75 (13.48, 30.93)	0.558	0.577
AST (U/L)	18.80 (11.80, 30.10)	16.25 (12.48, 24.80)	0.694	0.488
SUA (mmol/L)	312.51 ± 119.36	306.20 ± 102.97	0.323	0.747
Cre (mmol/L)	68.36 ± 27.54	70.16 ± 28.67	0.357	0.721
HbA1c (%)	5.30 (4.30, 6.60)	9.30 (8.18, 11.13)	9.013	0
FBG (mmol/L)	4.46 ± 0.89	10.08 ± 4.30	9.199	0
BMI (kg/m²)	25.15 ± 4.28BMI	25.55 ± 3.40	0.602	0.548
LDL-C (mmol/L)	2.30 (1.90, 3.30)	2.34 (1.94, 3.23)	0.201	0.84
TG (mmol/L)	1.40 (1.10, 2.30)	1.81 (1.09, 2.68)	1.581	0.144
TC (mmol/L)	4.45 ± 1.39	4.46 ± 1.29	0.049	0.961

T2DM: Type 2 diabetes mellitus; ALT: Alanine transaminase; AST: Aspartate transaminase; SUA: Serum uric acid; Cre: Creatinine; HbA1c: Glycosylated hemoglobin; FBG: Fasting blood sugar; BMI: Body mass index; LDL-C: Low-density lipoprotein cholesterol; TG: Triglycerides; TC: Total cholesterol.

Table 2 Comparison of carcinoembryonic antigen, cancer antigen 199, cancer antigen 242 between two groups

Variables	Control group (n = 51)	T2DM group (n = 82)	Z value	P value
CEA	2.10 (1.40, 2.70)	2.70 (1.90, 3.65)	3.279	0.000
CA199	7.60 (4.40, 10.10)	11.30 (5.57, 22.13)	3.976	0.000
CA242	6.10 (3.10, 6.90)	6.25 (4.13, 9.20)	0.891	0.373

CA: Cancer antigen; CEA: Carcinoembryonic antigen.

Table 3 Multivariate logistic regression analysis of factors associated with the onset of type 2 diabetes mellitus

Factors	β value	SE	Wald	P value	OR	95%CI
FBG	1.155	0.378	9.330	0.002	3.173	1.513-6.658
HBA1C	1.517	0.443	11.739	0.001	4.560	1.914-10.863
CEA	0.312	0.147	4.505	0.034	1.366	1.024-1.822
CA199	0.034	0.011	9.554	0.002	1.035	1.013-1.057
CA242	0.145	0.115	1.585	0.208	1.156	0.923-1.448

FBG: Fasting blood sugar; HbA1c: Glycosylated hemoglobin; CA: Cancer antigen; CEA: Carcinoembryonic antigen; OR: Odds ratio; 95%CI: 95% confidence interval.

Table 4 Comparison of general clinical characteristics and tumor marks of different glycosylated hemoglobin % diabetes patients

Variables	Group A (HbA1c ≤ 9%) (n = 37)	Group B (HbA1c > 9%) (n = 45)	t/Z value	P value
Age (yr)	60.08 ± 9.58	58.16 ± 13.05	0.747	0.457
Gender (male/female)	21/16	26/19	0.009	0.926
Course of disease (yr)	6 (3.00, 10.50)	9 (4, 15.00)	1.627	0.104
BMI (kg/m²)	26.09 ± 2.66	25.11 ± 3.88	1.349	0.181
FBG (mmol/L)	8.41 ± 2.79	11.46 ± 4.84	3.386	0.001
LDL-C (mmol/L)	2.33 (1.93, 3.02)	2.38 (1.94, 3.32)	0.680	0.496
TG (mmol/L)	2.00 (1.23, 3.01)	1.57 (0.96, 2.61)	1.142	0.254
TC (mmol/L)	4.54 ± 1.02	4.40 ± 1.48	0.494	0.623
Cre (umol/L)	71.07 ± 19.33	69.40 ± 34.72	0.261	0.795
SUA (umol/L)	333.64 ± 99.56	283.64 ± 101.27	2.242	0.028
ALT (U/L)	17.30 (12.65, 28.75)	19.90 (14.05, 31.45)	0.778	0.437
CEA (ng/mL)	1.90 (1.20, 2.60)	3.40 (2.60, 5.25)	5.488	0.000
CA199 (U/mL)	7.60 (4.15, 10.60)	21.00 (11.85, 26.85)	4.795	0.000
CA242 (U/mL)	5.90 (3.85, 7.15)	6.50 (4.80, 9.30)	1.622	0.105

HbA1c: Glycosylated hemoglobin; BMI: Body mass index; FBG: Fasting blood sugar; LDL-C: Low-density lipoprotein cholesterol; TG: Triglycerides; TC: Total cholesterol; Cre: Creatinine; SUA: Serum uric acid; ALT: Alanine transaminase; CA: Cancer antigen; CEA: Carcinoembryonic antigen.

Table 5 Correlation analysis of carcinoembryonic antigen, cancer antigen 199, cancer antigen 242 levels with glycosylated hemoglobin, fasting blood sugar and lipid metabolism in diabetes patients

Variables	CEA		CA199		CA242
Variables	r value	P value	r value	P value	r value	P value
HbA1c	0.308	0.000	0.426	0.000	0.551	0.000
FBG	0.236	0.033	0.231	0.037	0.298	0.006
LDL-C	0.138	0.216	0.238	0.032	0.240	0.030
TG	0.136	0. 222	0.105	0.346	0.051	0.649
TC	0.077	0.494	0.171	0.125	0.149	0.183

HbA1c: Glycosylated hemoglobin; FBG: Fasting blood sugar; LDL-C: Low-density lipoprotein cholesterol; TG: Triglycerides; TC: Total cholesterol.

Citation: Meng M, Shi LL. Serum tumor markers expression (CA199, CA242, and CEA) and its clinical implications in type 2 diabetes mellitus. World J Diabetes 2024; 15(2): 232-239
URL: https://www.wjgnet.com/1948-9358/full/v15/i2/232.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i2.232